Trials / Completed
CompletedNCT00937404
Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants
An Open-label Primary Vaccination Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Inactivated Poliomyelitis Vaccine Poliorix Administered as a Three-dose Primary Vaccination Course at 2, 3 and 4 Months of Age in Healthy Infants in China.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 60 Days – 90 Days
- Healthy volunteers
- Accepted
Summary
The study will evaluate the safety and reactogenicity of Poliorix given as primary vaccination course to Chinese children at 2, 3 and 4 months of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Poliorix | All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh. |
Timeline
- Start date
- 2009-08-04
- Primary completion
- 2009-11-13
- Completion
- 2009-11-13
- First posted
- 2009-07-13
- Last updated
- 2018-12-17
- Results posted
- 2018-12-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00937404. Inclusion in this directory is not an endorsement.